Table 1.
Characteristics of the patients at baseline (IRIVASC)
| Phenprocoumon (N = 95) | Rivaroxaban (N = 93) | |
|---|---|---|
| Median age (IQR), year | 72 (67–76) | 68 (65–75) |
| Male, no. (%) | 70 (73.6) | 65 (69.9) |
| Diabetes mellitus, no. (%) | 23 (24.7) | 26 (29.2) |
| Smoker, no. (%) | 11 (11.5) | 14 (15) |
| Non smoker, no. (%) | 39 (41) | 45 (48.3) |
| Ex. smoker, no. (%) | 42 (44.2) | 28 (30.1) |
| Previous MI, no. (%) | 25 (26.3) | 26 (27.9) |
| Previous stroke, no. (%) | 16 (16.8) | 8 (8.6) |
| Coronary heart disease (CHD), no. (%) | 51 (54.8) | 54 (60.6) |
| Median systolic blood pressure, right (IQR), mmHg | 130 (120–143,7) | 135,5 (122,7–149) |
| Median systolic blood pressure, left (IQR), mmHg | 130 (120–140) | 134 (124–145) |
| Median total cholesterol (IQR), mg/dl | 173 (149.7–204.2) | 176 (142–214.5) |
| Median LDL‐cholesterol (IQR), mg/dl | 109 (85.5–128,5) | 102.5 (82–138) |
| Median GFR (IQR), ml/min/1.73 m2 | 65.6 (52.8—81.5) | 72.3 (57.2–84.7) |
| Median hemoglobin (IQR), g/dl | 13.9 (13.2–15.2) | 14.2 (13.1–15) |
| Median CHA2DS2VASc score (IQR) | 3 (3–4) | 3 (2–4) |
| Indication for anticoagulation: | ||
| 1. Atrial fibrillation, no. (%) | 91 (95.8) | 90 (96.8) |
| 2. Pulmonary embolism, no. (%) | 4 (4.2) | 3 (3.2) |
| Type of atrial fibrillation | ||
| 1. Paroxysmal, no. (%) | 51 (56) | 57 (63.3) |
| 2. Persistent, no. (%) | 15 (16.5) | 14 (15.6) |
| 3. Permanent, no. (%) | 16 (17.6) | 15 (16.7) |
| 4. New onset, no. (%) | 1 (1.1) | 1 (1.1) |
| 5. Not further classified, no. (%) | 8 (8.8) | 3 (3.3) |